Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration

References

• Kukar M, Groman A, Malhotra U, Warren GW, Bogner P, Nwogu CE, Demmy TL, Yendamuri S. Small cell carcinoma of the esophagus: a SEER database analysis. Ann Surg Oncol. 2013;20(13):4239–8. doi:10.1245/s10434-013-3167-3.
   PubMed Web of Science ®Google Scholar
• Cai W, Ge W, Yuan Y, Ding K, Tan Y, Wu D, Hu H. A 10-year population-based study of the differences between NECs and carcinomas of the esophagus in terms of clinicopathology and survival. J Cancer. 2019;10(6):1520–7. doi:10.7150/jca.29483.
   PubMed Web of Science ®Google Scholar
• Yoshinami Y, Nishimura E, Hosokai T, Yamamoto S, Matsuda S, Nomura M, Kawakubo H, Kato K, Kitagawa Y. Rare malignant neoplasm of the esophagus: current status and future perspectives. Jpn J Clin Oncol. 2023;54(2):111–20.
   Web of Science ®Google Scholar
• Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):620–52. doi:10.3322/caac.21785.
   PubMed Web of Science ®Google Scholar
• Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–30. doi:10.1200/JCO.20.01055.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2021;22(1):51–65. doi:10.1016/S1470-2045(20)30539-8.
   PubMed Web of Science ®Google Scholar
• Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, Rodriguez L, Mishra-Kalyani P, Goldberg KB, Kluetz PG, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. The Oncologist. 2021;26(5):433–8. doi:10.1002/onco.13752.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393–422. doi:10.6004/jnccn.2023.0019.
   PubMedGoogle Scholar
• Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: now and future. World J Gastroenterol. 2023;29(34):5020–37. doi:10.3748/wjg.v29.i34.5020.
   PubMed Web of Science ®Google Scholar
• Ishida H, Kasajima A, Kamei T, Miura T, Oka N, Yazdani S, Ozawa Y, Fujishima F, Sakurada A, Nakamura Y, et al. SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis. Mod Pathol. 2017;30(5):660–71. doi:10.1038/modpathol.2016.222.
   PubMed Web of Science ®Google Scholar
• Li R, Yang Z, Shao F, Cheng H, Wen Y, Sun S, Guo W, Li Z, Zhang F, Xue L, et al. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nat Commun. 2021;12(1):3785. doi:10.1038/s41467-021-24043-6.
   PubMed Web of Science ®Google Scholar
• Ren W, Wu P, Tian J, Chen D, Li S, Liu B. Anti-PD-1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer: a case report. Thorac Cancer. 2021;12(2):264–7. doi:10.1111/1759-7714.13735.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu X, Liang H, Liu W, Wang H, Li T. Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report. J Int Med Res. 2023;51(7):3000605231187942. doi:10.1177/03000605231187942.
   Web of Science ®Google Scholar
• Liu L, Liu Y, Gong L, Zhang M, Wu W. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther. 2020;21(11):983–9. doi:10.1080/15384047.2020.1829265.
   PubMed Web of Science ®Google Scholar
• Wang F, Liu DB, Zhao Q, Chen G, Liu X-M, Wang Y-N, Su H, Qin Y-R, He Y-F, Zou Q-F, et al. The genomic landscape of small cell carcinoma of the esophagus. Cell Res. 2018;28(7):771–4. doi:10.1038/s41422-018-0039-1.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289–97. doi:10.1038/s41568-019-0133-9.
   PubMed Web of Science ®Google Scholar
• Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review. Diagnostics (Basel, Switzerland). 2015;5(2):119–76.
   PubMedGoogle Scholar
• Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol. 2020;31(7):844–60. doi:10.1016/j.annonc.2020.03.304.
   PubMed Web of Science ®Google Scholar
• Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68. doi:10.6004/jnccn.2021.0032.
   PubMedGoogle Scholar
• Wong AT, Shao M, Rineer J, Osborn V, Schwartz D, Schreiber D. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the national cancer data base. Dis Esophagus: Off J Int Soc Dis Esophagus. 2017;30(2):1–5. doi:10.1111/dote.12487.
   Web of Science ®Google Scholar
• Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, et al. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Med. 2020;9(2):595–604. doi:10.1002/cam4.2708.
   PubMed Web of Science ®Google Scholar
• Verma V, Sleightholm RL, Fang P, Ryckman JM, Lin C. National cancer database report of nonmetastatic esophageal small cell carcinoma. Cancer Med. 2018;7(12):6365–73. doi:10.1002/cam4.1712.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Abe H, Yamashita H, Yagi K, Seto Y, Ushiku T. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma. Histopathology. 2023;83(2):264–75. doi:10.1111/his.14924.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang G, Xue L, Zhang Z, Zeng Q, Wu P, Wang L, Yang Z, Zheng B, Tan F, et al. Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8+ T-cell infiltration in small cell carcinoma of the esophagus: a retrospective analysis of 34 years of national cancer center data in China. Int J Surg (London, England). 2023. Publish Ahead of Print. 10.1097/JS9.0000000000000064.
   Google Scholar
• Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300–12. doi:10.1038/s41571-019-0316-z.
   PubMed Web of Science ®Google Scholar